Clinical trials: in Moldova
Chronic Hepatitis Delta
Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)
The primary objective of this study is to evaluate the efficacy of bulevirtide in combination with pegylated interferon in participants with chronic hepatitis delta (CHD).
- Trial name
- NCT03852433
- Testing
- Bulevirtide, Peginterferon Alfa-2a (PEG-IFN alfa)
- Where
- 20 sites in France, Moldova and 2 more
- Volunteers
- 175 people
- Sponsor
- Gilead Sciences
Focal Epilepsy
A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy
The XEN1101 Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of increasing doses of XEN1101 administered as adjunctive treatment in…
- Trial name
- X-TOLE (NCT03796962)
- Testing
- XEN1101
- Where
- 95 sites in United States, Canada and 7 more
- Volunteers
- 325 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Healthy, Psoriasis
A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3970
The main purpose of this study is to evaluate the safety and tolerability of GLPG3970 in healthy volunteers after single oral administrations of GLPG3970 (SAD), compared to placebo (part 1 and 1bis) and after multiple (for 14…
- Trial name
- NCT04106297
- Testing
- GLPG3970 oral solution, GLPG3970 capsule
- Where
- 3 sites in Belgium, Moldova and 1 more
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Lakefront Biotherapeutics NV
Plaque Psoriasis
Safety, Tolerability, PK, PD and Preliminary Efficacy of ONO-4685
This is an early phase study to assess the safety and tolerability of ONO-4685 in patients with psoriasis. In addition, the study will assess how the drug is distributed and eliminated by the body (pharmacokinetics) and how the…
- Trial name
- NCT05332704
- Testing
- ONO-4685
- Where
- 4 sites in Moldova, Romania and 1 more
- Volunteers
- 33 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Cancer, Survivorship
Validation of the European Oncology Quality of Life Toolkit
The improvement or preservation of quality of life (QoL) is one of the three pillars of the European Union (EU) Mission on Cancer, which underpins the needs of patients from cancer diagnosis throughout treatment, survivorship…
- Conditions
- Cancer, Survivorship, Palliative Care
- Trial name
- NCT05947903
- Testing
- Administration of the EUonQoL-Kit - Active Treatment questionnaire, Administration of the EUonQoL-Kit - Survivors questionnaire, Administration of the EUonQoL-Kit - Palliative Care questionnaire
- Where
- 45 sites in Albania, Austria and 30 more
- Volunteers
- 4,000 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
COVID-19
Evaluation of ADG20 for the Prevention of COVID-19
This placebo-controlled study is intended to evaluate ADG20's safety and ability to prevent COVID-19 infection.
- Trial name
- EVADE (NCT04859517)
- Testing
- ADG20
- Where
- 95 sites in United States, Argentina and 7 more
- Volunteers
- 2,582 people
- Sponsor
- Invivyd, Inc.
Rheumatoid Arthritis
Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4
Olokizumab (OKZ) has been shown to reverse the inhibitory effect of IL-6 on the activity of Cytochrome P450 (CYP450) isozymes CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A4/5 in vitro.
- Trial name
- NCT04246762
- Testing
- Olokizumab, Omeprazole, Caffeine
- Where
- 2 sites in Bulgaria, Moldova
- Volunteers
- 17 people
- Sponsor
- R-Pharm International, LLC
TNBC - Triple-Negative Breast Cancer, Breast Cancer
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of trilaciclib versus placebo administered prior to gemcitabine and carboplatin in patients receiving first- or…
- Trial name
- PRESERVE 2 (NCT04799249)
- Testing
- Trilaciclib, Gemcitabine, Carboplatin
- Where
- 71 sites in United States, Australia and 9 more
- Volunteers
- 194 people
- Sponsor
- G1 Therapeutics, Inc.
NASH - Nonalcoholic Steatohepatitis
Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Subjects with biopsy-proven NASH will be randomly assigned in a 2:1 ratio to oral doses of namodenoson 25 mg every 12 hours or matching placebo every 12 hours for 36 weeks.
- Trial name
- NCT04697810
- Testing
- Namodenoson
- Where
- 24 sites in Bosnia and Herzegovina, Bulgaria and 4 more
- Volunteers
- 114 people
- Sponsor
- Can-Fite BioPharma
Advanced Solid Malignancies
Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies
This study is a single-arm, open-label, multi-centre drug-drug interaction (DDI) study of AZD5305 administered orally in patients with advanced solid tumours.
- Trial name
- NCT05573724
- Testing
- AZD5305, Itraconazole
- Where
- 2 sites in Moldova, Romania
- Volunteers
- 16 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis
Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Participants
The primary objective of the study was to evaluate the long-term safety and tolerability of filgotinib (formerly GLPG0634) for the treatment of rheumatoid arthritis.
- Trial name
- DARWIN3 (NCT02065700)
- Testing
- Filgotinib
- Where
- 111 sites in United States, Argentina and 20 more
- Volunteers
- 739 people
- Sponsor
- Lakefront Biotherapeutics NV
NSCLC
Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen
This is a Phase 2, open-label study to evaluate PD-1 inhibitor pimivalimab (JTX-4014) alone and in combination with vopratelimab (JTX-2011), an ICOS agonist, in biomarker-selected adult subjects with metastatic NSCLC who are…
- Trial name
- SELECT (NCT04549025)
- Testing
- Pimivalimab, Vopratelimab
- Where
- 72 sites in Belarus, Bosnia and Herzegovina and 12 more
- Volunteers
- 69 people
- Sponsor
- Jounce Therapeutics, Inc.
Hemophilia B
Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B
Phase 3/4, single arm, open-label study to evaluate PK, safety, and efficacy of APVO101 prophylaxis in severe or moderately severe hemophilia B subjects < 12 years of age.
- Trial name
- NCT03855280
- Testing
- APVO101
- Where
- 11 sites in Brazil, Georgia and 4 more
- Volunteers
- 21 people
- Sponsor
- Medexus Pharma, Inc.
Adolescent Behavior, Adolescent - Emotional Problem
Family-Focused Adolescent & Lifelong Health Promotion
The aim of this study is to adapt the Parenting for Lifelong Health for Parents and Teens (PLH) with the Helping Adolescents Thrive Comics in North Macedonia and the Republic of Moldova and conduct a pilot feasibility study of…
- Conditions
- Adolescent Behavior, Adolescent - Emotional Problem, Psychological Well-Being, Parent-Child Relations
- Trial name
- FLOURISH (NCT05930535)
- Testing
- Parenting for Lifelong Health for Parents and Teens
- Where
- 2 sites in Moldova, North Macedonia
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- University of Klagenfurt
Multiple Sclerosis
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis - CALLIPER
- Trial name
- CALLIPER (NCT05054140)
- Testing
- IMU-838
- Where
- 73 sites in United States, Bulgaria and 10 more
- Volunteers
- 450 people
- Sponsor
- Immunic AG
Chronic Hepatitis B
A Study of ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single Doses in Healthy Volunteers, and Single and Multiple Doses in CHB Subjects
A randomized study of ALG-125755 to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics after single doses in healthy volunteers, and single and multiple doses in CHB subjects
- Trial name
- NCT05561530
- Testing
- ALG-125755
- Where
- 4 sites in Bulgaria, Moldova and 2 more
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Aligos Therapeutics
Multiple Sclerosis, Relapsing-Remitting
IMCY-0141 Safety and Efficacy in Multiple Sclerosis - ISEMIS Study
The IMCY-MS-001 study is a study to test a new experimental drug, IMCY-0141, for the treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS).
- Trial name
- NCT05417269
- Testing
- IMCY-0141, Dimethyl Fumarate
- Where
- Moldova
- Volunteers
- 150 people
- Sponsor
- Imcyse SA
Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus
Study of M5049 in CLE and SLE Participants
This study is to evaluate the safety, tolerability and pharmacokinetics (PK) of orally administered M5049 in participants with systemic lupus erythematosus (SLE) or cutaneous lupus erythematosus (CLE).
- Trial name
- NCT04647708
- Testing
- M5049
- Where
- 12 sites in Bulgaria, Germany and 4 more
- Volunteers
- 25 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Ulcerative Colitis
Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC)
The principal aim of this study is to evaluate the safety and tolerability of RO7049665 in participants with active ulcerative colitis (UC).
- Trial name
- NCT03943550
- Testing
- RO7049665
- Where
- 6 sites in United States, Georgia and 3 more
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche
Ulcerative Colitis
An Investigation of Oral BT051 in Subjects With Moderately to Severely Active Ulcerative Colitis (UC)
This is a randomised, double-blind, placebo-controlled study to assess the safety and tolerability of multiple ascending doses of BT051 in subjects with moderately to severely active ulcerative colitis.
- Trial name
- SCOUT (NCT05084261)
- Testing
- BT051 200 mg, BT051 800 mg, BT051 3200 mg
- Where
- 6 sites in United States, Georgia and 2 more
- Volunteers
- 24 people
- Sponsor
- Adiso Therapeutics